Cutaneous Drug Eruptions Associated With the Use of New Oncological Drugs
TLDR New cancer drugs often cause skin and nail problems.
The document discussed cutaneous drug eruptions associated with new oncological drugs, highlighting that the skin was frequently involved in adverse drug reactions, with an incidence of 1-5% for certain drugs. These eruptions were mostly benign, including maculopapular eruptions and urticaria, but about one-third required hospital treatment, posing a significant burden on the healthcare system. The book provided a comprehensive overview of the field, covering epidemiology, genetic predisposition, and therapeutic measures such as rapid drug desensitization. It aimed to enhance understanding, diagnosis, and management of these eruptions for healthcare professionals, including general physicians, dermatologists, clinical allergologists, nurses, and scientists.
